Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy.

ABSTRACT:

Background

Tertiary lymphoid structures (TLSs) are linked to prognosis in esophageal squamous cell carcinoma (ESCC), but whether the distribution, abundance, and maturity of TLSs affect therapeutic efficacy and prognosis in ESCC treated with neoadjuvant chemoradiotherapy plus immunotherapy (NRCI) remains unclear. We explored TLS characteristics and correlated them with patient survival.

Methods

A total of 157 resectable ESCC patients treated with neoadjuvant therapy between September 2020 and May 2023 were divided into NRCI (n=49) and neoadjuvant chemoimmunotherapy (NCI, n=108) groups. Multiplex immunofluorescence (mIHC) was employed to compare the spatial distribution and cellular composition of TLSs in the NRCI (n=40) and NCI (n=40) groups. A TLSs scoring system assessed T

SUBMITTER: Zhai K 

PROVIDER: S-EPMC12411778 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature